Piper Sandler & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Piper Sandler & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-11,559	Closed	-$759K	–	24
2015 Q4	$759K	Buy	+11,559	New	+$714K	1.93%	8
2015 Q3	–	Sell	-14,500	Closed	-$857K	–	128
2015 Q2	$857K	Buy	+14,500	New	+$894K	0.51%	17
2015 Q1	–	Sell	-5,250	Closed	-$302K	–	146
2014 Q4	$302K	Buy	+5,250	New	+$292K	0.15%	55

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Piper Sandler & Co's TEVA Position: Q1 2016 in Review

Piper Sandler & Co sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 11,559 shares — an estimated $759K sold.

Piper Sandler & Co first reported a position in TEVA in Q4 2014 and held it in 3 quarters. The position peaked at $857K in Q2 2015. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Piper Sandler & Co reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Piper Sandler & Co sold 11,559 Teva Pharmaceuticals shares in Q1 2016, an estimated $759K.
Piper Sandler & Co first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 3 quarters.
Piper Sandler & Co's Teva Pharmaceuticals position peaked at $857K in Q2 2015.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Piper Sandler & Co's 13F filing for Q1 2016, filed 16 May 2016.